Use these links to rapidly review the document CHARLES RIVER LABORATORIES INTERNATIONAL, INC. FORM 10-Q For the Quarterly Period Ended June 26, 2004 Table of Contents
UNITED STATESSECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 10-Q
Commission file number 333-92383
CHARLES RIVER LABORATORIESINTERNATIONAL, INC. (Exact Name of Registrant as specified in its Charter)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ý No o
As of July 23, 2004, there were 46,205,337 shares of the registrant's common stock outstanding.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. FORM 10-Q For the Quarterly Period Ended June 26, 2004 Table of Contents
Special Note on Factors Affecting Future Results
This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. (Charles River) that are based on current expectations, estimates, forecasts and projections about the industries in which Charles River operates and the beliefs and assumptions of the management of Charles River. Words such as "expect," "anticipate," "target," "goal," "project," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Charles River's Annual Report on Form 10-K for the year ended December 27, 2003 under the section entitled "Risks Related to Our Business and Industry." Charles River undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
2
Part I. Financial Information
Item 1. Financial Statements
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (dollars in thousands, except per share amounts)
See Notes to Condensed Consolidated Financial Statements
3
4
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (dollars in thousands)
5
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (dollars in thousands)
6
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (dollars in thousands, except per share amounts)
1. Basis of Presentation
The condensed consolidated interim financial statements are unaudited, and certain information and footnote disclosures related thereto normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements were prepared following the same policies and procedures used in the preparation of the audited financial statements and reflect all adjustments (consisting of normal recurring adjustments) considered necessary to present fairly the financial position and results of operations of Charles River Laboratories International, Inc. (the "Company"). The results of operations for the interim periods are not necessarily indicative of the results for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 27, 2003.
Certain amounts in prior-year financial statements and related notes have been reclassified to conform with the current year presentation.
2. Business Acquisitions
On January 8, 2004, the Company acquired River Valley Farms, Inc. (RVF), a privately held medical device contract research business. Consideration, including acquisition expenses, was $16,972, net of cash acquired of $347. RVF was acquired to strengthen service offerings of the Company's existing development and safety testing (DST) segment. The acquisition was recorded as a purchase business combination in accordance with Statement of Financial Accounting Standards (SFAS) No. 141, "Business Combinations."
The preliminary purchase price allocations associated with the RVF acquisition are as follows:
Effective January 2, 2003, the Company acquired an additional 19% of the equity (404,321 common shares) of Charles River Japan from Ajinomoto Company, Inc., the minority interest partner, which increased the Company's ownership to 85% of the outstanding shares. The purchase price for the
7
equity was 1.3 billion yen, or $10,841, which was paid in cash. The Company recorded goodwill of $2,553 based on the preliminary purchase price allocation in the first quarter of 2003. The Company reallocated this amount to fixed assets based on an independent valuation of these fixed assets, which was completed during the second quarter of 2003. Charles River Japan is an extension of the Company's research models and services (RMS) segment.
The following selected unaudited pro forma consolidated results of operations are presented as if each acquisition had occurred as of the beginning of 2003, after giving effect to certain adjustments for additional interest expense and related income tax effects. The pro forma data is for informational purposes only and does not necessarily reflect the results of operations had the companies operated as one during the period. No effect has been given for synergies, if any, that may have been realized through the acquisitions.
Refer to Note 8 for further discussion of the method of computation of earnings per share.
3. Restructuring and Other Charges
Restructuring Charges
During the fourth quarter of 2001, the Company recorded restructuring charges of $1,788, including asset disposals of $1,041, employee separation of $477 and other charges of $270, associated with the closure of a facility in San Diego, California. The restructuring plan included the termination of approximately 40 employees and the exit of a facility utilized under an operating lease. During 2002, the Company recorded an additional $292 charge relating to the facility's lease obligation based on the Company's revised estimate of expected sublease income generated over the remaining lease term. During the third quarter of 2003, the Company recorded an additional $404 charge relating to the remaining lease obligation at the facility due to adverse rental market conditions in the San Diego area. The San Diego facility was included in the DST segment.
During the fourth quarter of 2000, the Company recorded restructuring charges of $1,290, including asset disposal of $212, associated with the closure of a facility in France. During 2001, the Company recorded additional charges of $1,915, which included a write down of assets held for sale of $400 and additional severance payments and other related expenses of $1,515, relating to the settlement of labor disputes which originated during the first quarter of 2001. Approximately 60 employees were terminated as a result of the restructuring. The French facility was included in the RMS segment.
8
Other Charges
During the second and third quarters of 2003, the Company recorded a total charge of $954, included in the DST segment, for severance to employees who were terminated as part of a cost savings program. The Company recorded $690 of the charge in cost of services provided and $264 in selling, general and administrative expenses in the condensed consolidated statements of income. Approximately 100 employees, mainly technicians, technical support and administrative staff, were terminated as part of the cost savings program.
During the first quarter of 2003, the Company re-evaluated the marketability of certain long-lived assets related to a biopharmaceutical production facility in Maryland, which is included in the DST segment, due to a significant decline in market interest in purchasing these assets. Since the Company was unable to locate a buyer for these assets, an impairment charge was recognized because future undiscounted cash flows were estimated to be insufficient to recover the related book value. The Company recorded an asset impairment charge of $3,655 for the write-down of those assets including a net write-down of leasehold improvements of $2,195 and machinery and equipment of $1,460. The charge was recorded as other operating expenses in the condensed consolidated statements of income. The Company closed the Maryland facility during 2003.
A summary of the activities associated with the above restructuring and other charges and the related liabilities balance is as follows:
The Company has closed both the San Diego facility and the French facility and expects the reserves to be fully utilized by the end of 2005. All terminated employees had separated from the Company by the end of the third quarter of 2002.
4. Litigation Settlement
On March 28, 2003, the Company's French subsidiaries, which are included in the RMS segment, settled a pending breach of contract claim against a customer. The Company's French subsidiaries had previously been awarded damages of approximately $4,600 by the Commercial Court of Lyon and the damages award was stayed pending appeal by the customer at the French Supreme Court. The final settlement of this dispute was for a gross value of approximately $3,750, resulting in the retention by the Company's French subsidiaries of that amount previously deposited by the customer, pursuant to the order of the Commercial Court of Lyon, and recorded in deferred income in the condensed consolidated balance sheet. During 2000, the Company recognized approximately $350 of the damages
9
award to offset a portion of subcontractor costs incurred based on the indemnification clause in the original customer agreement. After legal and related expenses, the Company's French subsidiaries recorded a net gain for the retained settlement amount of $2,908, which was recorded in the first quarter of 2003 as other operating income in the condensed consolidated statements of income.
5. Supplemental Balance Sheet Information
The composition of inventories is as follows:
The composition of other current assets is as follows:
The composition of property, plant and equipment is as follows:
Depreciation expense for the six months ended June 26, 2004 and June 28, 2003 was $13,144 and $11,578, respectively.
10
The composition of other assets is as follows:
The composition of other current liabilities is as follows:
The composition of other long-term liabilities is as follows:
11
6. Goodwill and Other Intangible Assets
The following table displays goodwill and other intangible assets not subject to amortization and other intangible assets that continue to be subject to amortization:
The changes in the gross carrying amount and accumulated amortization of goodwill from December 27, 2003 to June 26, 2004 are as follows:
Estimated amortization expense for each of the next five fiscal years is as follows:
12
7. Long-Term Debt
On March 31, 2003, the Company entered into a revolving credit agreement which matures on March 31, 2006. The agreement permits the Company to borrow up to $100,000 at an interest rate based on, at the Company's option, the greater of either the Prime Rate, the Base CD Rate plus 1% and the Federal Funds Effective Rate plus 0.5%, or LIBOR multiplied by the Statutory Reserve Rate plus a spread of 1.25% to 2.50% based on the leverage ratio of the Company and the aggregate borrowing under the revolving credit agreement. Interest is payable based on the Company's selected interest rate, which ranges from monthly to semi-annually. The credit agreement requires the Company to pay a quarterly commitment fee which ranges from 25 through 50 basis points annually on the undrawn balance based on the leverage of the Company. The agreement also requires the Company to remain in compliance with certain financial ratios as well as other restrictive covenants. There were no amounts outstanding under the credit agreement as of June 26, 2004.
8. Shareholders' Equity
Earnings per Share
Basic earnings per share for the three and six months ended June 26, 2004 and June 28, 2003 were computed by dividing earnings available to common shareholders for these periods by the weighted average number of common shares outstanding in the respective periods adjusted for contingently issuable shares. The weighted average number of common shares outstanding in the three and six months ended June 26, 2004 and June 28, 2003 have been adjusted to include common stock equivalents for the purpose of calculating diluted earnings per share for this period.
Options to purchase 26,800 and 1,888,065 shares were outstanding in each of the respective three months ended June 26, 2004 and June 28, 2003 but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Options to purchase 1,320,600 and 1,868,065 shares were outstanding in each of the respective six months ended June 26, 2004 and June 28, 2003 but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive.
Basic weighted average shares outstanding for the three and six months ended June 26, 2004 and June 28, 2003 excluded the weighted average impact of 20,000 shares of contingently issuable shares. In addition, basic weighted average shares outstanding for the three and six months ended June 26, 2004 and June 28, 2003 excluded the weighted average impact of 90,839 and 61,669 shares, respectively, of non-vested fixed restricted stock awards.
13
The following table illustrates the reconciliation of the numerator and denominator of the basic and diluted earnings per share computations:
Comprehensive Income
The components of comprehensive income for the three and six months ended June 26, 2004 and June 28, 2003 are set forth below:
9. Income Taxes
In the first quarter of 2004, the Company reorganized its European operations. The purpose of the reorganization was to streamline the legal entity structure in order to improve operating efficiency and
14
cash management, facilitate acquisitions and provide tax benefits. The reorganization, which did not involve reductions of personnel or facility closures, resulted in a one-time, non-cash charge to earnings in the first quarter of 2004 of $7,900 due primarily to the write-off of a deferred tax asset.
In light of this reorganization, the Company reassessed the valuation allowance associated with its foreign tax credit carryforwards. As a result of this reassessment, $2,111 of the valuation allowance was released and recorded as a tax benefit in the first quarter of 2004.
The following table provides a reconciliation of the provision for income taxes on the condensed consolidated statement of income:
10. Employee Benefits
The following table provides the components of net periodic benefit cost for the Company's defined benefit plans:
Pension Benefits
15
Supplemental Retirement Benefits
The Company contributed $193 and $383 to its pension plans during the three and six months ended June 26, 2004.
11. Stock-Based Compensation Plans
SFAS No. 123, "Accounting for Stock-Based Compensation," requires the presentation of certain pro forma information as if the Company had accounted for its employee stock options under the fair value method. For purposes of this disclosure, the fair value of the fixed option grants was estimated using the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility and expected life of the options. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimates, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. However, for each period presented, management believes the Black-Scholes model is the most appropriate option valuation model for the Company's options.
Had compensation expense for the Company's option grants been determined consistent with the provision of SFAS No. 123, as amended by SFAS No. 148, "Accounting for Stock-Based Compensation—Transition and Disclosure, an Amendment of FASB Statement No. 123," the
16
Company's net income for the three and six months ended June 26, 2004 and June 28, 2003 would have been reduced to the pro forma amounts indicated below:
Restricted Common Stock and Performance Based Plans
Under the Company's 2000 Incentive Plan, restricted common stock of the Company may be granted at no cost to officers and key employees. Plan participants are entitled to cash dividends, if declared, and to vote their respective shares. Restrictions limit the sale or transfer of these shares until they vest, which is typically over a three-year period. Upon issuance of restricted stock awards under the plan, unearned compensation equivalent to the market value at the date of grant is charged to shareholders' equity and subsequently amortized to expense over the vesting period. On February 13, 2004, the Company granted 18,700 restricted stock awards and recorded $805 as unearned compensation in shareholders' equity. During the three months ended June 26, 2004 and June 28, 2003, the Company recorded $505 and $315, respectively, and during the six months ended June 26, 2004 and June 28, 2003, the Company recorded $927 and $412, respectively, in compensation expense for restricted stock awards.
In the first quarter of 2004, the Company's Board of Directors initiated a new performance-based management incentive program (Mid-Term Incentive (MTI) Program), as a carve-out from the shareholder approved 2000 Incentive Plan. For 2004, the MTI Program provides that up to a maximum of 218,000 performance units may be granted to senior executives and certain other key employees of the Company based on achieving financial performance targets for 2006. The MTI Program units, which equal the value of one share of Company stock, will be paid out to participating employees in the form of cash and restricted stock. Management anticipates that following the planned merger with Inveresk, the 2006 revenue and operating income targets that trigger the maximum unit payments are likely to be achieved. For a participant to be eligible to receive payment for 2004 MTI units, the
17
employee must remain employed with the Company until at least the beginning of 2007. The restricted stock, which requires continued employment beyond 2007, vests over the ensuing two-year period.
The Company will accrue compensation expense for the 2004 MTI Program obligations over the period the participating employees are required to be employed by the Company. During the three and six months ended June 26, 2004, the Company recorded $1,022 and $1,316, respectively, as compensation expense for the 2004 MTI Program. In each of the respective three and six months ended June 26, 2004, $486 and $662 was recorded as capital in excess of par value in shareholders' equity, and the remaining $536 and $654 was recorded as accrued compensation. The accrual for the MTI Program is marked to market on a quarterly basis. Accordingly, changes in the market value of Company stock could materially affect this compensation expense. Based upon our share price of $47.25 as of June 25, 2004 our maximum payment obligation under the 2004 MTI Program would be approximately $10 million.
12. Commitments and Contingencies
Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. In the opinion of management, the outcome of such proceedings and litigation currently pending will not materially affect the Company's consolidated financial statements.
As of June 26, 2004 and December 27, 2003, the Company had $4,763 and $5,313 under letters of credit outstanding, respectively.
13. Business Segment Information
The following table presents sales to unaffiliated customers and other financial information by product line segment for the three and six months ended June 26, 2004 and June 28, 2003.
18
A reconciliation of segment operating income to consolidated operating income is as follows:
A summary of unallocated corporate overhead consists of the following:
Other general unallocated corporate expenses consist of various departmental costs including corporate accounting, legal and investor relations.
During the fourth quarter of 2003, the Company revised its consolidated financial reporting segments to better reflect the manner in which the Company's operating units are managed. The Company believed the revision was required because in 2003 a number of changes were made to align related businesses, to focus sales force responsibilities and to simplify management structure. The Company continues to report two segments, now called Research Models and Services (RMS) segment and Development and Safety Testing (DST) segment. The research models business continues to be reported in the RMS segment and transgenic services, laboratory services, contract staffing services and vaccine support services are now reported in the RMS segment. The Company reports development services, including drug safety testing, pathology services and interventional and surgical services, and in vitro technology in the DST segment. The changes in segment presentation have no effect on consolidated revenues or net income. Management believes that the new business segments better reflect results of operations and facilitate investors' understanding of the Company's business. Prior year segment information has been reclassified to reflect current year presentation.
14. Recently Issued Accounting Standards
In January 2003, FASB issued Interpretation No. 46 (FIN 46), "Consolidation of Variable Interest Entities," which clarifies the application of Accounting Research Bulletin (ARB) No. 51, "Consolidated
19
Financial Statements," relating to consolidation of certain entities. First, FIN 46 will require identification of the Company's participation in variable interest entities (VIE), which are defined as entities with a level of invested equity that is not sufficient to fund future activities to permit them to operate on a stand alone basis, or whose equity holders lack certain characteristics of a controlling financial interest. Then, for entities identified as VIE, FIN 46 sets forth a model to evaluate potential consolidation based on an assessment of which party to the VIE, if any, bears a majority of the exposure to its expected losses, or stands to gain from a majority of its expected returns. In December 2003, the FASB issued a revised FIN 46 to defer the effective date and provide further clarification on the interpretation. FIN 46R is effective for public companies in the first fiscal period after December 15, 2003. The adoption of FIN 46 did not have a material effect on the Company's results of operations and financial condition.
15. Subsequent Events
On June 30, 2004, the Company and Inveresk Research Group, Inc. (Inveresk) entered into a definitive merger agreement. Inveresk is a leading provider of drug development services to companies in the pharmaceutical and biotechnology industry. Under the terms of the agreement, Inveresk shareholders will receive 0.48 shares of the Company's common stock and $15.15 in cash for each share of Inveresk common stock they own, representing a total consideration of $38.61 per common share, or a transaction value of approximately $1.5 billion, based on the Company's closing price on June 30, 2004, of $48.87 per share. Following the close of the transaction, the Company's shareholders will own approximately 73% of the fully diluted shares of the new company, and Inveresk shareholders will own approximately 27%. The Company entered into the merger agreement to combine and expand the service portfolios of the two companies and strengthen its global presence in the growing market for pharmaceutical research and development products and services. On July 20, 2004, the Federal Trade Commission granted early termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvement Act in connection with the proposed merger. The transaction is subject to customary closing conditions, including additional regulatory and shareholder approvals. The merger is expected to close in the fourth quarter of 2004. As of June 26, 2004, the Company capitalized $1.6 million of external audit, legal and other related service costs associated with the merger. The capitalized costs were recorded in other assets in the condensed consolidated balance sheet.
20
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our condensed consolidated financial statements and the related notes.
Overview
We are a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. We are a global leader in providing the animal research models and services required in research and development for new drugs, devices and therapies and have been in business since 1947. We have two segments for financial reporting purposes: Research Models and Services (RMS) and Development and Safety Testing (DST).
On June 30, 2004, we signed a definitive merger agreement with Inveresk Research Group, Inc. (Inveresk) which would create a leading global partner in providing essential preclinical and clinical drug development services and products to the pharmaceutical and biotechnology industry. The strategic combination will significantly expand our service portfolio and strengthen our global footprint in the growing market for pharmaceutical research and development products and services. A copy of the merger agreement is filed as an exhibit to this report. The combination with Inveresk will create a company with approximately $920 million in revenues based upon the twelve months ended March 2004, with substantial profitability and strong cash flow, giving it the size and financial stability to support the growing demand for outsourced development services from international pharmaceutical and biotechnology companies. The combined company will have operations throughout the United States, Canada, Europe and Japan. Under the terms of the merger agreement, Inveresk shareholders will receive 0.48 shares of Charles River common stock and $15.15 in cash for each share of Inveresk common stock they own. On July 20, 2004, the Federal Trade Commission granted early termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvement Act in connection with the proposed merger. The transaction is subject to customary closing conditions, including additional regulatory and shareholder approvals. The merger is expected to close in the fourth quarter of 2004.
Our second quarter sales reflect the continued strong spending by major pharmaceuticals, biotechnology companies and academic institutions on our global products and services which aid in their development of new drugs and products. Total net sales in the second quarter of 2004 were $180.2 million, an increase of 16.7% over the same period last year. Our gross margin increased to 41.4% of net sales in the second quarter of 2004, compared to 38.6% of net sales for the same period last year, due to improved utilization as a result of the increased sales in the DST segment. Last year, we implemented a cost savings program for our DST segment which resulted in a severance charge of $0.9 million during the second quarter of 2003. Operating income increased 26.3% to $44.2 million in the second quarter of 2004 from $35.0 million for the same period last year. The operating margin increased to 24.5% in the second quarter of 2004 compared to 22.7% last year. Net income was $26.3 million in the second quarter of 2004, a 27.9% increase compared to $20.6 million for the same period last year. Diluted earnings per share for the second quarter of 2004 were $0.52 compared to $0.42 for the same period last year.
On a year to date basis, total net sales were $352.8 million, an increase of 15.1% over the same period last year due to growth in both DST and RMS. Our gross margin increased to 40.7% of total net sales, compared to 38.4% of total net sales for the same period last year. Operating income on a year to date basis increased 21.6% over last year. On a year to date basis, the operating margin increased to 23.7% compared to 22.5% for last year. In the first quarter of 2004, we reorganized our European operations to streamline the legal entity structure in order to improve operating efficiency and cash management, facilitate acquisitions and provide tax benefits. The reorganization, which did not involve reductions of personnel or facility closures, resulted in a one-time, non-cash charge to earnings in the first quarter of 2004 of $7.9 million due to the write-off of a deferred tax asset. In light of this reorganization, we reassessed the valuation allowance associated with our foreign tax credit
21
carryforwards and released $2.1 million as a tax benefit. Net income on a year to date basis was $43.9 million, including the write-off of the deferred tax asset and the reversal of a valuation allowance, compared to $39.9 million for the same period last year.
Our RMS business segment represented 62.9% of net sales in the second quarter of 2004. Net sales for this segment increased 10.6% over the same period last year. The primary contributors to this growth were price increases and volume with foreign exchange accounting for a small portion of the increase. We are in the process of adding and evaluating capacity for RMS worldwide. Operating income as a percent of net sales increased to 33.5% compared to 31.0% for last year.
Sales on a year to date basis for our RMS business segment increased 10.3% over the same period last year. The net sales increase drove an improvement in operating income. Operating income was $74.5 million, an increase of $5.5 million from last year's second quarter. Operating income from last year's second quarter included a favorable litigation settlement of $2.9 million.
Our DST segment represented 37.1% of net sales in the second quarter of 2004. Sales for this segment increased 28.9% over the same period last year. Our development services business continued to recover from the slower demand for toxicology services that we experienced in 2003. We believe the market for toxicology services, which was at a low point during early 2003, continues to recover, particularly in high-end specialty services. Our efforts to integrate and harmonize the development services business and to focus its sales efforts positioned it to benefit from stronger customer demand for outsourced services, particularly in general and specialty toxicology. The market improvement has reduced the excess capacity and moderated the price sensitivity for services. We added capacity in two of our facilities in 2003, and based on our projected demand for these services, we expect to add both general and specialty toxicology capacity to accommodate market growth in 2005 and beyond. The acquisition of RVF contributed 5.1% to the net sales growth in the second quarter of 2004. The DST operating margin improved significantly for the second quarter of 2004 to 21.6%, compared to 14.1% for the same period last year. The increase was primarily due to higher sales and improved capacity utilization.
Sales on a year to date basis for our DST segment increased 24.9% over the same period last year. Operating income increased to 19.3% of net sales through the second quarter of 2004, compared to 8.2% through the second quarter of 2003. Operating income for the six months ending June 28, 2003 included the impairment charge of $3.7 million for our contract manufacturing facility and the $0.9 million severance charge.
During the first quarter of 2004 we adopted a mid-term incentive (MTI) program in which performance units are paid to senior executives and certain other employees in the form of cash and restricted stock based upon achieving financial performance targets for the Company in 2006. We recorded expense in the first and second quarters to reflect management's expectations for performance under this program, including the favorable impact of the proposed combination with Inveresk. See Footnote 11 for additional information on the MTI Program.
Three Months Ended June 26, 2004 Compared to Three Months Ended June 28, 2003
Net Sales. Net sales for the three months ended June 26, 2004 were $180.2 million, an increase of $25.8 million, or 16.7%, from $154.4 million for the three months ended June 28, 2003. The increase in net sales was primarily due to continued strong spending by pharmaceutical and biotechnology companies for our global products and services. Favorable foreign currency translation contributed approximately 2% to our net sales gain. River Valley Farms, Inc. (RVF), which we acquired on January 8, 2004, contributed 1.7% to our net sales growth.
Research Models & Services. For the three months ended June 26, 2004, RMS net sales were $113.3 million, an increase of $10.8 million, or 10.6%, compared to $102.5 million for the three months ended June 28, 2003. RMS prices increased at certain geographical locations in a range up to 8% with
22
an average increase of approximately 5%. RMS segment volume increased but was negatively impacted by the following factors: the loss of a significant contract for contract staffing services in the fourth quarter of 2003, the bankruptcy of a biotechnology customer and the merger of two customers in the second quarter of 2003. Net sales to these customers in the second quarter of 2004 declined by more than $2 million from the second quarter of last year. Favorable foreign currency translation contributed approximately 3% to our net sales gain.
Development & Safety Testing. For the three months ended June 26, 2004, DST net sales were $66.9 million, an increase of $15.0 million, or 28.9%, from $51.9 million for the three months ended June 28, 2003. DST sales increased in 2004 primarily due to our development services group recovering from the slower demand for toxicology services we experienced during 2003. Customer demand has increased from the low point we experienced in the first quarter of 2003. We believe the market capacity is in line with customer demand moderating price sensitivity for specialty services. The acquisition of RVF contributed 5.1% to the net sales growth and favorable foreign currency translation contributed approximately 1%.
Cost of Products Sold and Services Provided. Cost of products sold and services provided for the three months ended June 26, 2004 was $105.6 million, an increase of $10.8 million, or 11.4%, from $94.8 million for the three months ended June 28, 2003. Cost of products sold and services provided for the three months ended June 26, 2004 was 58.6% of net sales, compared to 61.4% for the three months ended June 28, 2003. The decrease in cost of products sold and services provided as a percent of sales was due primarily to increased capacity utilization in DST and RMS.
Research Models & Services. Cost of products sold and services provided for RMS for the three months ended June 26, 2004 was $63.9 million, an increase of $4.5 million, or 7.5%, compared to $59.4 million for the three months ended June 28, 2003. Cost of products sold and services provided as a percentage of net sales decreased to 56.4% for the three months ended June 26, 2004 from 58.0% for the three months ended June 28, 2003. The decrease in cost of product sold and services provided as a percentage of net sales was primarily due to improved capacity utilization and greater operating efficiencies.
Development & Safety Testing. Cost of products sold and services provided for DST for the three months ended June 26, 2004 was $41.6 million, an increase of $6.3 million, or 17.8%, compared to $35.3 million for the three months ended June 28, 2003. Cost of products sold and services provided for the three months ended June 26, 2004 decreased to 62.3% of net sales compared to 68.1% of net sales for the three months ended June 28, 2003. The decrease in cost of products sold and services provided as a percentage of net sales was due primarily to improved capacity utilization from the increased sales of toxicology services.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended June 26, 2004 were $29.2 million, an increase of $5.9 million, or 25.1%, from $23.3 million for the three months ended June 28, 2003. Selling, general and administrative expenses for the three months ended June 26, 2004 and were 16.2% of net sales, compared to 15.1% of net sales for the three months ended June 28, 2003. The increase in selling, general and administrative expenses for the three months ended June 26, 2004 was due primarily to higher anticipated bonuses and stock based compensation, as well as, increased professional fees including compliance with the internal control certification requirements of Sarbanes-Oxley.
Research Models & Services. Selling, general and administrative expenses for RMS for the three months ended June 26, 2004 were $11.4 million, an increase of $0.4 million, or 2.8%, compared to $11.0 million for the three months ended June 28, 2003. Selling, general and administrative expenses for the three months ended June 26, 2004 decreased to 10.0% of net sales, compared to 10.8% of net sales for the three months ended June 28, 2003. The decrease in selling, general and administrative
23
expenses as a percentage of net sales for the three months ended June 26, 2004 was primarily due to greater economies of scale.
Development & Safety Testing. Selling, general and administrative expenses for DST for the three months ended June 26, 2004 were $9.6 million, an increase of $1.4 million, or 17.6%, compared to $8.2 million for the three months ended June 28, 2003. Selling, general and administrative expenses for the three months ended June 26, 2004 were 14.4% of net sales, compared to 15.8% for the three months ended June 28, 2003. The decrease in selling, general and administrative expenses as a percent of sales for the three months ended June 26, 2004 was primarily due to our continued ability to manage costs in line with our sales increase.
Unallocated Corporate Overhead. Unallocated corporate overhead, which consists of various corporate expenses including those associated with pension, executive salaries and departments such as corporate accounting, legal and investor relations, was $8.2 million for the three months ended June 26, 2004, compared to $4.1 million for the three months ended June 28, 2003. The increase in unallocated corporate overhead for the three months ended June 26, 2004 was due mainly to costs associated with increased anticipated bonuses and stock based compensation, as well as, increased professional fees including compliance with the internal control certification requirements of Sarbanes-Oxley.
Amortization of Other Intangibles. Amortization of other intangibles for the three months ended June 26, 2004 was $1.2 million, which was essentially flat compared to the three months ended June 28, 2003.
Operating Income. Operating income for the three months ended June 26, 2004 was $44.2 million, an increase of $9.2 million, or 26.3%, from $35.0 million for the three months ended June 28, 2003. Operating income for the three months ended June 26, 2004 was 24.5% of net sales, compared to 22.7% of net sales for the three months ended June 28, 2003.
Research Models & Services. For the three months ended June 26, 2004, operating income from our RMS segment was $38.0 million, an increase of $6.2 million, or 19.5%, from $31.8 million for the three months ended June 28, 2003. Operating income for the three months ended June 26, 2004 increased to 33.5% of net sales, compared to 31.0% of net sales for the three months ended June 28, 2003. The increase in operating income for the three months ended June 26, 2004 was primarily due to increased sales and higher gross margins.
Development & Safety Testing. For the three months ended June 26, 2004, operating income from our DST segment was $14.4 million, an increase of $7.1 million, from $7.3 million for the three months ended June 28, 2003. Operating income for the three months ended June 26, 2004 was 21.6% of net sales, compared to 14.1% for the three months ended June 28, 2003. The increase in operating income for the three months ended June 26, 2004 was primarily due to the continued recovery of the market for outsourced development services which resulted in higher sales and greater utilization.
Interest Expense. Interest expense for the three months ended June 26, 2004 was $2.1 million, which was essentially flat compared to the three months ended June 28, 2003.
Income Taxes. Income tax expense for the three months ended June 26, 2004 was $16.1 million, an increase of $3.1 million compared to $13.0 million last year. Our effective tax rate for the three months ended June 26, 2004 was 37.5% compared to the second quarter rate of 38.5% in 2003, due to the benefit of the reorganization of our European operations.
Net Income. Net income for the three months ended June 26, 2004 was $26.3 million, a increase of $5.7 million, or 27.9%, from $20.6 million for the three months ended June 28, 2003.
24
Six Months Ended June 26, 2004 Compared to Six Months Ended June 28, 2003
Net Sales. Net sales for the six months ended June 26, 2004 were $352.8 million, an increase of $46.3 million, or 15.1%, from $306.5 million for the six months ended June 28, 2003. The increase in net sales was primarily due to continued strong spending by pharmaceutical and biotechnology companies on our global products and services. Favorable foreign currency translation contributed approximately 3% to our net sales gain. River Valley Farms, Inc. (RVF), which we acquired on January 8, 2004, contributed 1.7% to our net sales growth.
Research Models & Services. For the six months ended June 26, 2004, RMS net sales were $226.8 million, an increase of $21.2 million, or 10.3%, compared to $205.6 million for the six months ended June 28, 2003. RMS prices increased at certain geographical locations in a range up to 8% with an average increase of approximately 5%. RMS segment volume increased but was negatively impacted by the following factors: the loss of a significant contract for contract staffing services in the fourth quarter of 2003, the bankruptcy of a biotechnology customer and the merger of two customers in the second quarter of 2003. Net sales to these customers in the six months ended June 26, 2004 declined by more than $6 million from the six months ended June 28, 2003. Favorable foreign currency translation contributed approximately 4% to our net sales gain.
Development & Safety Testing. For the six months ended June 26, 2004, DST net sales were $126.0 million, an increase of $25.1 million, or 24.9%, from $100.9 million for the six months ended June 28, 2003. DST sales increased in 2004 primarily due to our development services business recovering from the slower demand for toxicology services we experienced during 2003. Customer demand has increased from the low point we experienced in the first quarter of 2003. We believe the market capacity is in line with customer demand, moderating price sensitivity. The acquisition of RVF contributed 5.2% to the net sales growth and favorable foreign currency translation contributed approximately 1%.
Cost of Products Sold and Services Provided. Cost of products sold and services provided for the six months ended June 26, 2004 was $209.4 million, an increase of $20.5 million, or 10.8%, from $188.9 million for the six months ended June 28, 2003. Cost of products sold and services provided for the six months ended June 26, 2004 was 59.3% of net sales, compared to 61.6% for the six months ended June 28, 2003. The decrease in cost of products sold and services provided as a percent of sales was due primarily to increased capacity utilization in DST and RMS.
Research Models & Services. Cost of products sold and services provided for RMS for the six months ended June 26, 2004 was $128.5 million, an increase of $10.8 million, or 9.2%, compared to $117.7 million for the six months ended June 28, 2003. Cost of products sold and services provided as a percentage of net sales decreased to 56.7% for the six months ended June 26, 2004 from 57.2% for the six months ended June 28, 2003. The decrease in cost of product sold and services provided as a percentage of net sales was primarily due to improved capacity utilization and greater operating efficiencies.
Development & Safety Testing. Cost of products sold and services provided for DST for the six months ended June 26, 2004 was $80.9 million, an increase of $9.7 million, or 13.5%, compared to $71.2 million for the six months ended June 28, 2003. Cost of products sold and services provided for the six months ended June 26, 2004 decreased to 64.2% of net sales compared to 70.6% of net sales for the six months ended June 28, 2003. The decrease in cost of products sold and services provided as a percentage of net sales was due primarily to improved capacity utilization from the increased sales of toxicology services.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended June 26, 2004 were $57.3 million, an increase of $11.8 million, or 26.1%, from $45.5 million for the six months ended June 28, 2003. Selling, general and administrative expenses for
25
the six months ended June 26, 2004 were 16.3% of net sales, compared to 14.8% of net sales for the six months ended June 28, 2003. The increase in selling, general and administrative expenses for the six months ended June 26, 2004 was due primarily to one-time costs associated with the European reorganization, increased bonus and stock based compensation expense, severance costs in Europe not related to the European reorganization and increased professional fees including compliance with the internal control certification requirements of Sarbanes-Oxley.
Research Models & Services. Selling, general and administrative expenses for RMS for the six months ended June 26, 2004 were $23.7 million, an increase of $2.3 million, or 10.9%, compared to $21.4 million for the six months ended June 28, 2003. Selling, general and administrative expenses for the six months ended June 26, 2004 increased to 10.5% of net sales, compared to 10.4% of net sales for the six months ended June 28, 2003. The increase in selling, general and administrative expenses for the six months ended June 26, 2004 was primarily due to severance costs in Europe and the impact of foreign exchange, partially offset by cost savings due to greater economies of scale.
Development & Safety Testing. Selling, general and administrative expenses for DST for the six months ended June 26, 2004 were $18.6 million, an increase of $2.9 million, or 18.6%, compared to $15.7 million for the six months ended June 28, 2003. Selling, general and administrative expenses for the six months ended June 26, 2004 were 14.7% of net sales, compared to 15.5% for the six months ended June 28, 2003. The decrease in selling, general and administrative expenses as a percent of sales for the six months ended June 26, 2004 was primarily due to our continued ability to manage costs in line with our sales increase.
Unallocated Corporate Overhead. Unallocated corporate overhead, which consists of various corporate expenses including those associated with pension, executive salaries and departments such as corporate accounting, legal and investor relations, was $15.0 million for the six months ended June 26, 2004, compared to $8.4 million for the six months ended June 28, 2003. The increase in unallocated corporate overhead for the six months ended June 26, 2004 was due to costs associated with the European reorganization, increased bonus and stock based compensation expense and increased professional fees including compliance with the internal control certification requirements of Sarbanes-Oxley.
Other Operating Expenses, Net. During the first quarter of 2003, we recorded a $3.7 million charge associated with the closure of a contract manufacturing facility. Also during 2003, our French subsidiaries settled a breach of contract claim they had asserted against a customer. After legal and related expenses, the net settlement amounted to a gain of approximately $2.9 million.
Amortization of Other Intangibles. Amortization of other intangibles for the six months ended June 26, 2004 was $2.4 million, which was essentially flat compared to the six months ended June 28, 2003.
Operating Income. Operating income for the six months ended June 26, 2004 was $83.7 million, an increase of $14.8 million, or 21.6%, from $68.9 million for the six months ended June 28, 2003. Operating income for the six months ended June 26, 2004 was 23.7% of net sales, compared to 22.5% of net sales for the six months ended June 28, 2003.
Research Models & Services. For the six months ended June 26, 2004, operating income from our RMS segment was $74.5 million, an increase of $5.5 million, or 7.9%, from $69.0 million for the six months ended June 28, 2003. Operating income for the six months ended June 26, 2004 decreased to 32.8% of net sales, compared to 33.6% of net sales for the six months ended June 28, 2003. The decrease in operating income for the six months ended June 26, 2004 was primarily due to the prior year gain on the settlement of a breach of contract claim of $2.9 million, or 1.4% of sales.
26
Development & Safety Testing. For the six months ended June 26, 2004, operating income from our DST segment was $24.3 million, an increase of $16.0 million, almost double the $8.3 million for the six months ended June 28, 2003. Operating income for the six months ended June 26, 2004 was 19.3% of net sales, compared to 8.2% for the six months ended June 28, 2003. The increase in operating income for the six months ended June 26, 2004 was primarily due to the continued recovery of the market for outsourced development services and the prior year charge associated with the closure of a contract manufacturing facility of $3.7 million, or 3.7% of sales.
Interest Expense. Interest expense for the six months ended June 26, 2004 was $4.2 million, essentially flat compared to the six months ended June 28, 2003.
Income Taxes. Income tax expense for the six months ended June 26, 2004 was $36.2 million, an increase of $10.8 million compared to $25.4 million last year. Our effective tax rate for the six months ended June 26, 2004 was 44.6%. Excluding charges associated with the deferred tax write-off and the benefit from the reversal of the valuation allowance, the effective tax rate for the six months ended June 26, 2004 was 37.5%, compared to the six months ended June 28, 2003 rate of 38.5%, due to the benefit of the reorganization of our European operations.
Net Income. Net income for the six months ended June 26, 2004 was $43.9 million, an increase of $4.0 million, or 10.0%, from $39.9 million for the six months ended June 28, 2003. Net income for the six months ended June 26, 2004 included charges associated with the write-off of the deferred tax asset of $7.9 million and the benefit from the reversal of a valuation allowance of $2.1 million.
Liquidity and Capital Resources
The following discussion analyzes liquidity and capital resources by operating, investing and financing activities as presented in our condensed consolidated statements of cash flows.
Our principal sources of liquidity have been our cash flows from operations, our revolving line of credit arrangements, and proceeds from our debt and equity offerings.
On June 30, 2004, we signed a definitive merger agreement with Inveresk Research Group, Inc. Under the terms of the merger agreement, Inveresk shareholders will receive 0.48 shares of Charles River common stock and $15.15 in cash for each share of Inveresk common stock they own. We expect the cash portion of the transaction, including fees and expenses, will be approximately $600 million as of June 30, 2004. We will utilize some of our existing cash and proceeds from additional borrowing to fund the cash portion of the transaction. We currently have a commitment from our lenders for $500 million of financing subject to customary conditions.
On January 8, 2004, we acquired River Valley Farms, Inc. (RVF), a privately held medical device contract research business. Consideration, including acquisition expenses, was $17.0 million, net of cash acquired of $0.3 million. RVF was acquired to strengthen the service offerings of our DST segment.
On March 31, 2003, we entered into a revolving credit agreement which matures on March 31, 2006. The agreement permits us to borrow up to $100.0 million at an interest rate based on, at the Company's option, the greater of either the Prime Rate, the Base CD Rate plus 1%, and the Federal Funds Effective Rate plus 0.5%, or LIBOR multiplied by the Statutory Reserve Rate plus a spread of 1.25% to 2.50% based on our leverage ratio and the aggregate borrowing under the revolving credit agreement. Interest is payable based on our selected interest rate, which ranges from monthly to semi-annually. The credit agreement requires us to pay a quarterly commitment fee which ranges from 25 through 50 basis points on the undrawn balance based on our leverage ratio. The agreement also requires us to remain in compliance with certain financial ratios as well as other restrictive covenants. Some of the restrictive covenants limit our ability to acquire companies, increase our debt and pay dividends. The revolving credit agreement will be terminated upon closing of the Inveresk transaction. There were no amounts outstanding under the credit agreement as of June 26, 2004.
27
Effective January 2, 2003, we acquired an additional 19% of the equity (404,321 common shares) of our then 66% equity joint venture company, Charles River Japan, from Ajinomoto Company, Inc. The purchase price for the equity was 1.3 billion yen, or $10.8 million, which was paid in cash.
In connection with the acquisition of Springborn Laboratories, Inc. in 2002, we entered into a $6.0 million three-year unsecured subordinated note. The note was payable in three equal annual installments of principal, together with interest accrued in arrears commencing on October 1, 2003. The note was repaid in full during 2003.
We anticipate that our operating cash flows will be sufficient to meet our anticipated future operating expenses, capital expenditures and debt service obligations as they become due. We currently intend to retain any earnings to finance future operations, expansion and acquisitions. Charles River Laboratories International, Inc. is a holding company with ownership of 100% of the common stock of its subsidiary, Charles River Laboratories, Inc.
Cash and cash equivalents totaled $224.2 million at June 28, 2004, compared to $182.3 million at December 27, 2003.
Net cash provided by operating activities for the six months ended June 26, 2004 and June 28, 2003 was $68.2 million and $49.3 million, respectively. The increase in cash provided by operating activities was primarily due to increased net income, the non-cash write-off of the deferred tax asset in the first quarter and increased accrued compensation. Our days sales outstanding remained flat at 64 days as of June 26, 2004 compared to June 28, 2003, but improved from 67 days as of December 27, 2003.
Net cash used in investing activities for the six months ended June 26, 2004 and June 28, 2003 was $30.7 million and $25.0 million, respectively. For the six months ended June 26, 2004, we used $11.9 million for capital expenditures and $17.0 million to acquire RVF. This compared to 2003 during which we paid $10.8 million for the acquisition of an additional 19% of the equity of Charles River Japan and $14.5 million for capital expenditures. In 2004, we made capital expenditures in RMS and DST which were $7.5 million and $4.4 million, respectively. We anticipate that future capital expenditures will be funded by cash provided by operating activities. For fiscal 2004, we project capital expenditure to be approximately $40 million.
Net cash provided by and (used in) financing activities for the six months ended June 26, 2004 and June 28, 2003 was $6.1 million and ($3.9) million, respectively. Proceeds from exercises of employee stock options amounted to $7.9 million and $1.3 million for the six months ended June 26, 2004 and June 28, 2003, respectively. During the first quarter of 2004, we borrowed and repaid $94.0 million as part of our European reorganization. In 2003, payments and proceeds on long term debt were ($5.9) million and $2.5 million, respectively, for the six months ended June 28, 2003.
Off-Balance Sheet Arrangements
We had no off-balance sheet arrangements during the six months ended June 26, 2004.
Recently Issued Accounting Pronouncements
In January 2003, FASB issued Interpretation No. 46 (FIN 46), "Consolidation of Variable Interest Entities," which clarifies the application of Accounting Research Bulletin (ARB) No. 51, "Consolidated Financial Statements," relating to consolidation of certain entities. First, FIN 46 will require identification of the Company's participation in variable interest entities (VIE), which are defined as entities with a level of invested equity that is not sufficient to fund future activities to permit them to operate on a stand alone basis, or whose equity holders lack certain characteristics of a controlling financial interest. Then, for entities identified as VIE, FIN 46 sets forth a model to evaluate potential consolidation based on an assessment of which party to the VIE, if any, bears a majority of the exposure to its expected losses, or stands to gain from a majority of its expected returns. In
28
December 2003, the FASB issued a revised FIN 46 to defer the effective date and provide further clarification on the interpretation. FIN 46R is effective for public companies in the first fiscal period after December 15, 2003. The adoption of FIN 46 did not have a material effect on the Company's results of operations and financial condition.
Item 3. Quantitative and Qualitative Disclosure About Market Risk
Certain of our financial instruments are subject to market risks, including interest rate risk and foreign currency exchange rates. We generally do not use financial instruments for trading or other speculative purposes.
Interest Rate Risk
The fair value of our marketable securities is subject to interest rate risk and will fall in value if market interest rates increase. If market rates were to increase immediately and uniformly by 100 basis points from levels at June 26, 2004, then the fair value of the portfolio would decline by approximately $0.1 million.
The fair value of long-term fixed interest rate debt is subject to interest rate risk. In addition, the fair value of our senior convertible debentures would be impacted by our stock price. The estimated fair value of our long-term debt at June 26, 2004 was $233.6 million. Fair values were determined from available market prices, using current interest rates and terms to maturity.
Our senior convertible debentures accrue interest at an initial rate of 3.5%, which will be reset (but not below the initial rate of 3.5% or above 5.25%) on August 1, 2007, August 1, 2012 and August 1, 2016. Fluctuations in interest rates will not affect the interest payable on the senior convertible debentures, which is fixed through August 1, 2007.
Foreign Currency Exchange Rate
We also have exposures to some foreign currency exchange rate fluctuations for the cash flows received from our foreign affiliates. This risk is mitigated by the fact that their operations are principally conducted in their respective local currencies. Currently, we do not engage in any foreign currency hedging activities.
Item 4. Controls and Procedures
Based on their evaluation, required by paragraph (b) of Rules 13a-15 or 15d-15, promulgated by the Securities Exchange Act of 1934 (the "Exchange Act"), the Company's principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act are effective as of June 26, 2004 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.
There were no changes in the Company's internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of the Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended June 26, 2004 that materially affected, or were reasonably likely to materially affect, the Company's internal control over financial reporting.
29
Part II. Other Information
Item 4. Submission of Matters to a Vote of Security Holders
At the Company's Annual Meeting of Shareholders held on May 12, 2004, the following proposals were adopted by the votes specified below:
30
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits.
(b) Reports on Form 8-K.
On April 29, 2004, the Company furnished a current report on Form 8-K under Item 12 (Results of Operations and Financial Condition) containing a copy of a press release providing financial results for the fiscal quarter ended March 27, 2004.
31
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
32